.jpg)
STAT+: A gene therapy designed to heal skin wounds helped preserve a boy’s vision
In the clinical trial, the gene therapy seemed to be helping the boy’s skin wounds…
Category: STAT+
STAT+: Government warns Medicare Advantage insurers not to deny care based on AI
In recent months, the federal government has repeatedly told Medicare Advantage insurers that they cannot…
STAT+: Mystery of allergic memory gets closer to answer: a rare group of B cells
Maria Curotto de Lafaille’s lab was trying to make human plasma cells in a dish….
STAT+: Years into an addiction crisis, a med school lecture still minimized opioid risks
Amid ongoing concern over opioid addiction, a university in Florida has been criticized for allowing…
STAT+: Pharmalittle: We’re reading about worries over a Novo deal, a PBM bill, and more
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: RayzeBio co-founder, industry veterans launch new biotech VC with $310 million
Three biotech VC veterans, including one of the co-founders of radiopharma success story RayzeBio, are…
STAT+: AI can speed up drug discovery but don’t expect it to cure cancer, yet
David Reese calls it a “hinge moment” — the turning point when biotech and big…
STAT+: Health care developers are impressed by Apple Vision Pro, but they aren’t diving head first
Apple has long touted the potential of the iPhone and Apple Watch to help people…
STAT+: House panel passes key PBM reform for sliver of commercial market
WASHINGTON — A House panel passed a bipartisan bill to ban drug middlemen from charging…
STAT+: Why Eli Lilly’s earnings didn’t quite live up to the hype
Eventually, the luckiest companies get to deal with a very particular problem: what to do…
STAT+: Colombia proceeds with plans to issue a compulsory license for an HIV medicine sold by GSK’s ViiV
The Colombian government has taken a significant step toward issuing a compulsory license for a…
STAT+: Why Novartis is going to walk away from its acquisition of MorphoSys
Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The…
.jpg)
STAT+: Pharmalittle: We’re reading about a lawsuit against J&J, Express Scripts dealings, and more
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: Eli Lilly reports tirzepatide MASH success during Q4 earnings
The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve…
STAT+: Novartis to buy German biotech MorphoSys for $2.9 billion
Novartis said late Monday it has agreed to buy German biotech MorphoSys and its pipeline…
STAT+: Cano Health’s downfall offers a warning for Medicare Advantage
Private Medicare just isn’t the gold mine it once was. Case in point: Cano Health,…
STAT+: The lone Democrat willing to weaken Medicare’s power to negotiate drug prices
WASHINGTON — Two Republican lawmakers who introduced legislation to water down the Inflation Reduction Act’s…
STAT+: Diabetes treatments have improperly listed patents that should be removed, analysis finds
More than half of the injector-pen patents for several widely used diabetes treatments — including…
STAT+: Novo’s Catalent deal is great for GLP-1s. But what about drug manufacturing?
Sixteen billion dollars is a lot of money. But Monday’s announcement that the parent company…
STAT+: Pharmalittle: We’re reading about Novo buying Catalent, Amgen’s obesity drug, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Novo Holdings to purchase drug manufacturer Catalent for $16.5 billion, a deal that could expand Wegovy production
LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent…
STAT+: New Medicare Advantage rule is boon for providers, drag on insurers
Starting this year, private Medicare plans have to cover their members’ hospitalizations at the higher…
STAT+: Devoted Health’s losses in Medicare Advantage persist
Devoted Health has been one of the most prominent health insurance and provider startups of…
STAT+: Juul spent big to court Black leaders to promote its e-cigarettes, new documents show
Documents released this week shed new light on an aggressive strategy from vape maker Juul…
STAT+: ARCH Venture Partners is raising $3 billion for a life sciences fund
ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3…
STAT+: The lessons of Aduhelm, Biogen’s Alzheimer’s drug that was not to be
Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy,…
STAT+: Senate working group proposes 340B reforms
WASHINGTON — A bipartisan group of senators released a draft of legislation to resolve controversial…
STAT+: AI therapy and ICU training: A first look at health apps for Apple Vision Pro
Apple Vision Pro, the company’s most important new product in a decade, promises to envelop…
STAT+: Pharmalittle: We’re reading about opioid settlements, an OTC birth control pill, and more
And so, another working week will soon draw to a close. Not a moment too…
Medicare drug price negotiation’s day in court
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: Pharmalittle: We’re reading about Medicare price negotiations, slowing layoffs, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Biden administration makes opening offers in Medicare drug price negotiations
WASHINGTON — The Biden administration is making its opening offers to pharmaceutical companies in its…
STAT+: General Catalyst wants to take over a safety-net health system in Akron. The city has questions
General Catalysts’s grand vision for a venture capital-owned hospital system seamlessly blending AI and tech…
STAT+: Can gene therapies make for a profitable business? Keep your eye on Bluebird Bio
Happy Groundhog Day eve. Some takes and thoughts on Bluebird Bio’s quest for gene therapy…
STAT+: Obscure vertigo drug could bring rare hope for patients with devastating neuron disease
About a decade ago, Tatiana Bremova-Ertl’s graduate adviser was studying an obscure, 1950s-era French vertigo…
STAT+: Judge skeptical of arguments against Medicare drug price negotiation
WILMINGTON, Del. — Today was the first time that a federal judge asked questions in-person…
STAT+: WTO appears close to rejecting a proposed waiver on patents for Covid diagnostics and therapies
After more than a year of deliberation, the World Trade Organization appears close to rejecting…
STAT+: Pharmalittle: We’re reading about Wegovy supplies, Biogen ditching Aduhelm, and more
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: Years after a polarizing approval, Biogen walks away from Aduhelm
Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval…
STAT+: Experts critique flawed system for monitoring drugs’ side effects in wake of asthma drug report
After a drug enters the market, it’s up to Food and Drug Administration regulators to…
STAT+: As supply crunch starts to ease, Novo Nordisk to offer more doses of obesity drug Wegovy to U.S. patients
LONDON — Novo Nordisk said Wednesday that it had started to increase the availability of…
STAT+: Vertex pain drug results met with measured optimism — and questions — by observers and experts
Late-stage trial results for a pain medication developed by Vertex Pharmaceuticals reinforced experts’ sense that…
STAT+: CMS will use outcomes-based agreements in bid to help Medicaid pay for sickle cell gene therapies
In response to concerns over multimillion-dollar price tags for new gene therapies for sickle cell…
STAT+: Here are the new hotspots for Boston-area biotech
Move over, Kendall Square. Folks in the biotech nerve center may shudder at the notion….
STAT+: Pharmalittle: We’re reading about a Vertex pain pill, an abortion pill hearing, and more
Top of the morning to you. And a fine one it is. Despite gray skies,…
STAT+: Vertex’s closely-watched pain relief drug succeeds in late-stage trials — with a catch
A pain relief drug developed by Vertex Pharmaceuticals succeeded in late-stage clinical trials, the company…
STAT+: Cour Pharmaceuticals, a biotech taking aim at autoimmune diseases, raises $105 million
John Puisis was dubious when he first heard about the autoimmune science being developed by…
STAT+: Ultima Genomics launching high-end DNA sequencers that can read genome for $100
Ultima Genomics, an upstart some observers have called a “dark horse” in the world of…
STAT+: Can Wegovy treat depression as well as obesity? New research looks to GLP-1 drugs for mental illnesses
Drugs like Ozempic and Wegovy — already game changers for diabetes and obesity — are…
STAT+: FDA’s Woodcock reflects on more than 30 years at agency — and hints at what’s next
WASHINGTON — It’s the end of an era for the Food and Drug Administration’s longtime…